Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Hagberg

Showing results (241-250 of 244) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 244 results.
ESMO Open|July 16, 2021
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)M Eriksson, P Reichardt, H Joensuu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.
Cell Death & Disease|September 2, 2011
Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitorD Chauvier, S Renolleau, S Holifanjaniaina, et al.
Pageof 25

Showing results (241-250 of 244) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 244 results.
ESMO Open|July 16, 2021
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)M Eriksson, P Reichardt, H Joensuu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.
Cell Death & Disease|September 2, 2011
Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitorD Chauvier, S Renolleau, S Holifanjaniaina, et al.
Pageof 25